The PMPRB (Patented Medicine Prices Review Board) has announced that they have further delayed the enforcement of the amended “Patented Medicines Regulations” to July 1, 2021. This is good news for all Canadians since the regulations which were revised to lower drug prices, have instead created barriers to new medicines for rare diseases.

The regulations as newly drafted and subsequently revised are not in line with what most stake-holders (including the vast majority of patient groups) wanted to see because the concerns raised during consultations have been largely ignored.

The announcement of the delay can be viewed here:
https://www.canada.ca/en/patented-medicine-prices-review/services/consultations/draft-guidelines.html… » Read More

Markham family applauds rare disease funding… » Read More

Brampton man with rare disease says Queen’s Park funding needs clarity… » Read More

Statement from the Office of the Hon. Dr. Eric Hoskins
Ontario’s Minister of Health and Long-Term Care… » Read More

Thousands of Ontarians support ultra-rare disease group’s plea for public funding of life-saving drug

Media Advisory – aHUS Canada Action Day

The quest for Soliris … » Read More

First NICE highly specialised technologies guidance recommends eculizumab (Soliris) for treating very rare life-threatening blood disorder … » Read More